Epigenetics in Precision Medicine: From Mechanism to Therapy

A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Epigenetic Therapy".

Deadline for manuscript submissions: 30 November 2025 | Viewed by 742

Special Issue Editors


E-Mail Website
Guest Editor
Department of Biomedicine and Prevention, University of Rome “Tor Vergata”, Rome, Italy
Interests: Genetics; Epigenetics; Pharmacogenomics; Multifactorial Diseases; Autoimmune Diseases; microRNAs.
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Department of Clinical Medicine, Life, Health and Environmental Sciences - MESVA, University of L’Aquila, 67100 Coppito, AQ, Italy
Interests: Epigenetics; Genomics; Metabolic Disorders; Complex Diseases, DNA methylation.

Special Issue Information

Dear Colleagues,

We are pleased to invite you to participate in this new Special Issue, entitled “Epigenetics in Precision Medicine: From Mechanism to Therapy”, of the Journal of Personalized Medicine, which highlights the latest discoveries regarding epigenetics applied to the field of personalized medicine. Precision medicine aims to tailor medical treatments to the individual characteristics of each patient, including genetic, environmental, and lifestyle information. The integration of epigenetics in precision medicine offers a huge potential to improve the diagnosis, prognosis, and treatment of various diseases. Epigenetic factors can, in fact, represent specific biomarkers for different diseases, counting on the identification of individuals at risk before the onset of symptoms or to make a precise and timely diagnosis. They can also provide prognostic information, helping to predict the course of the disease and the response to treatment. Recent studies have also suggested how therapies can be adapted to the patient’s epigenetic profile. Epigenetic drugs, such as histone deacetylase inhibitors and DNA methyltransferase inhibitors, have also been developed, which can modify the aberrant gene expression associated with the disease. The integration of epigenetic information with genomic and clinical data allows a more complete understanding of the underlying mechanisms of the disease and a greater ability to personalize treatments, thus improving patient outcomes. With this Special Issue, we invite specialists from all faculties to contribute to this exciting field of research.

Dr. Andrea Latini
Dr. Valerio Caputo
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • epigenetics
  • precision medicine
  • methylation
  • histone modifications
  • non-coding RNA

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

26 pages, 4862 KiB  
Article
Integrative Analysis of DNA Methylation and microRNA Reveals GNPDA1 and SLC25A16 Related to Biopsychosocial Factors Among Taiwanese Women with a Family History of Breast Cancer
by Sabiah Khairi, Chih-Yang Wang, Gangga Anuraga, Fidelia Berenice Prayugo, Muhamad Ansar, Mohammad Hendra Setia Lesmana, Lalu Muhammad Irham, Chen-Yang Shen and Min-Huey Chung
J. Pers. Med. 2025, 15(4), 134; https://doi.org/10.3390/jpm15040134 - 30 Mar 2025
Viewed by 495
Abstract
Biopsychosocial factors, including family history, influence the development of breast cancer. Malignancies in women with a family history of breast cancer may be detectable based on DNA methylation and microRNA. Objectives: The present study extended an integrative analysis of DNA methylation and [...] Read more.
Biopsychosocial factors, including family history, influence the development of breast cancer. Malignancies in women with a family history of breast cancer may be detectable based on DNA methylation and microRNA. Objectives: The present study extended an integrative analysis of DNA methylation and microRNA to identify genes associated with biopsychosocial factors. Methods: We identified 3060 healthy women from the Taiwan Biobank and included 32 blood plasma samples for analysis of biopsychosocial factors and epigenetic changes. GEO databases and bioinformatics approaches were used for the identification and validation of potential genes. Results: Our integrative analysis revealed GNPDA1 and SLC25A16 as potential genes. Age, a family history of cancer, and alcohol consumption were associated with GNPDA1 and SLC25A16 based on the current data set and the GEO data set. GNPDA1 and SLC25A16 exhibited significant expression in breast cancer tissues based on UALCAN analysis, where they were overexpressed and underexpressed, respectively. Through a MethSurv analysis, GNPDA1 hypomethylation and SLC25A16 hypermethylation were associated with poor prognoses in terms of overall survival in breast cancer. Moreover, through a MetaCore functional enrichment analysis, GNPDA1 and SLC25A16 were associated with the BRCA1, BRCA2, and pro-oncogenic actions of the androgen receptor in breast cancer. Further, GNPDA1 and SLC25A16 were enriched in known targets of approved cancer drugs as potential genes associated with breast cancer. Conclusions: These two genes might serve as biomarkers for the early detection of breast cancer, especially for women with a family history of breast cancer. Full article
(This article belongs to the Special Issue Epigenetics in Precision Medicine: From Mechanism to Therapy)
Show Figures

Figure 1

Back to TopTop